PURCHASE, N.Y., Oct.
31, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the“Company” or“Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented participant baseline characteristics in the Phase 2 'SHIMMER' study of mild-to-moderate dementia with Lewy bodies (DLB). The poster is being presented at the 17th Annual Clinical Trials on Alzheimer's disease (CTAD) conference being held October 29 – November 1, 2024 in Madrid, Spain and is available on Cognition's website .
“Looking at the mean scores, participants who entered our DLB study had mild-to-moderate levels of cognitive impairment; the severity of their fluctuations in attention were consistent with a clinical diagnosis of DLB; and most participants had mild movement impairment,” explained Anthony Caggiano, M.D., Ph.
D. , Cognition's CMO and head of R&D. Baseline characteristics of the 130 participants enrolled in the study, as described in the poster: “DLB is one of the most common forms of dementia and a complex neurological condition.
Symptoms include cognitive, motor, psychological and behavioral impairment that change over time as the disease progresses,” stated Lisa Ricciardi, Cognition's president and CEO .“These characteristics are similar to participant demographics from other signal-finding studies in DLB. We look forward to reading out the results of our study later this year.
” CTAD Poster Details: About Dementia with .
